Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCNIC.L Regulatory News (CNIC)

  • There is currently no data for CNIC

Share Buyback Programme

30 Dec 2022 07:00

RNS Number : 2607L
CentralNic Group PLC
30 December 2022
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

30 December 2022

 

CENTRALNIC GROUP PLC

("CentralNic" or "the Company" or "the Group")

 

Share Buyback Programme

CentralNic Group Plc (AIM: CNIC), the global internet software company that derives recurring revenue from marketplaces for Online Presence and Online Marketing services, further to its announcement on 12 December 2022, is pleased to inform that its maiden share buyback programme of ordinary shares of £0.001 each ("Ordinary Shares") up to a maximum aggregate consideration of £4 million (the "Buyback Programme") launches effective today.

The Board considers the Buyback Programme to be in the best interests of all shareholders, given the cash generative nature of the business and the strong performance compared to expectations. It reflects the Group's more balanced future approach to capital allocation.

The Company has appointed its broker, Zeus Capital Limited ("Zeus"), to manage the Buyback Programme to repurchase Ordinary Shares on its behalf and entered into an irrevocable and non-discretionary arrangement on 29 December 2022 with Zeus and Arden Partners PLC to enable Zeus to conduct the Buyback Programme on a broker-managed basis. Zeus will make trading decisions in relation to the Buyback Programme independently of the Company, within certain defined parameters.

The Buyback Programme commences today and will end no later than the date upon which the aggregate consideration paid for Ordinary Shares reaches £4 million, or by the time of the Company's 2023 Annual General Meeting which is to be held no later than 30 June 2023 (the "Buyback Period"). During the Buyback Period the Company has no power to invoke any changes to the authority and any purchases will be undertaken by Zeus, acting independently of, and uninfluenced by the Company.

 

Ordinary Share repurchases will take place in open market transactions and may be made from time to time depending on market conditions, share price and trading volume. The Buyback Programme is in accordance with the Company's general authority to purchase a maximum of 28,866,000 Ordinary Shares, granted by its shareholders at the Annual General Meeting held on 4 May 2022, including that the maximum price paid per Ordinary Share will be no more than: a) 105 per cent. of the average trading price of the Ordinary Shares as derived from the middle market quotations for an Ordinary Share on the London Stock Exchange Daily Official List for the five trading days immediately preceding the date on which an Ordinary Share is contracted to be purchased; and b) the higher of the price of the last independent trade and the highest current independent purchase bid for Ordinary Shares on the trading venue where the purchase is carried out.

 

Under the Buyback Programme, the repurchased shares will either be cancelled or held in treasury at the Company's discretion for later reissue or cancellation. Shares held in treasury are not entitled to dividends and have no voting rights at the Company's general meetings.

 

The Buyback Programme will be conducted within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (each as in force in the UK from time to time, including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019.

 

The Company will make further announcements in due course following any share purchases conducted through the Buyback Programme.

 

The Company confirms that it currently has no unpublished price sensitive information.

 

For further information:

 

CentralNic Group Plc

 

Michael Riedl, Chief Executive Officer

+44 (0) 203 388 0600

 

Don Baladasan, Group Managing Director

 

 

 

 

Zeus (NOMAD and Broker)

 

Nick Cowles / Jamie Peel / James Edis (Investment Banking)

+44 (0) 161 831 1512

Dominic King (Corporate Broking) 

+44 (0) 203 829 5000

 

 

Berenberg (Joint Broker)

Mark Whitmore / Richard Andrews / Alix Mecklenburg-Solodkoff

 

SEC Newgate (for Media)

+44 (0) 20 3207 7800

 

Bob Huxford / Harry Handyside

 

+44 (0) 203 757 6880

centralnic@secnewgate.co.uk

 

 

 

The person responsible for arranging for the release of this announcement on behalf of CentralNic is Michael Riedl, CEO

 

About CentralNic Group Plc

CentralNic (AIM: CNIC) is a London-based AIM-listed company which drives the growth of the global digital economy by developing and managing online marketplaces allowing businesses globally to buy subscriptions to domain names for websites and email, monetise their websites, and acquire customers online. Its core growth strategy is identifying and acquiring cash-generative businesses in its industry with annuity revenue streams and exposure to growth markets and migrating them onto the CentralNic software and operating platforms. For more information please visit: www.centralnicgroup.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFEWEEUEESEIE
Date   Source Headline
25th Apr 20237:00 amRNSResult of AGM
24th Apr 20237:01 amRNSBoard Changes
24th Apr 20237:00 amRNSTrading Update
17th Apr 20237:00 amRNSDirectors' Dealings
17th Apr 20237:00 amRNSShare Awards and Exercise of Options
14th Apr 202311:01 amRNSDirectors' Dealings and Holdings in Company
11th Apr 20233:08 pmRNSDirectors' Dealings
5th Apr 20234:13 pmRNSDirectors' Dealings
3rd Apr 20237:00 amRNSDirectors' Dealings
30th Mar 20238:56 amRNSDirectors’ Dealings
27th Mar 20233:26 pmRNSDirectors’ Dealings
27th Mar 20237:00 amRNSAnnual Report, Notice of Q1 Update, AGM & Dividend
22nd Mar 20231:35 pmRNSDirectors’ Dealings
17th Mar 20234:00 pmRNSHolding(s) in Company
17th Mar 20237:00 amRNSDirectors’ Dealings
16th Mar 20237:00 amRNSHolding(s) in Company
14th Mar 20237:00 amRNSDirectors' Dealings
10th Mar 20237:15 amEQSCentralNic (CNIC): Clarifying the narrative
9th Mar 20237:00 amRNSDirectors’ Dealings
6th Mar 20237:00 amRNSDirectors' Dealings
2nd Mar 20237:00 amRNSCentralNic among FT's fastest growing in Europe
27th Feb 20237:00 amRNSUnaudited Preliminary Accounts for Full Year 2022
31st Jan 20237:00 amRNSPartnership Announcement
30th Jan 20237:00 amRNSTrading Update, Board Changes, Notice of Results
25th Jan 20238:08 amRNSDirectors' Dealings
23rd Jan 20237:00 amRNSDirector Dealings
20th Jan 20237:00 amRNSNotification of Major Holdings
20th Jan 20237:00 amRNSDirectors' Dealings
19th Jan 20237:00 amRNSTransaction in Own Shares
17th Jan 20237:00 amRNSDirectors' Dealings
17th Jan 20237:00 amRNSTransaction in Own Shares
16th Jan 20237:00 amRNSTransaction in Own Shares
13th Jan 20237:00 amRNSTransaction in Own Shares
12th Jan 20238:14 amRNSDirectors' Dealings
12th Jan 20237:00 amRNSTransaction in Own Shares
11th Jan 20237:00 amRNSTransaction in Own Shares
10th Jan 20237:00 amRNSTransaction in Own Shares
10th Jan 20237:00 amRNSHolding(s) in Company
9th Jan 20234:17 pmRNSDirectors' Dealings
9th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20238:13 amRNSShare Awards and exercise of Options
6th Jan 20237:00 amRNSTransaction in Own Shares
5th Jan 20237:00 amRNSTransaction in Own Shares
4th Jan 20237:00 amRNSTransaction in Own Shares
3rd Jan 20237:00 amRNSDirectors' Dealings
3rd Jan 20237:00 amRNSTransaction in Own Shares
30th Dec 20227:00 amRNSShare Buyback Programme
21st Dec 20226:17 pmRNSDirectors' Dealings
19th Dec 20227:00 amRNSAcquisition Announcement
16th Dec 20225:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.